A Phase II Study of Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Condition:   PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment Intervention:   Drug: Orevogomab+PLD Sponsor:   Yonsei University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials